Inherited copper transport disorders: Biochemical mechanisms, diagnosis, and treatment

Current Drug Metabolism

Volumn 13, Issue 3, 2012, Pages 237-250

  Kodama, Hiroko ^a,b   Fujisawa, Chie ^a   Bhadhprasit, Wattanaporn ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b TEIKYO HEISEI UNIVERSITY   (Japan)

Author keywords

ATP7A; ATP7B; Disulfiram; Menkes disease; Occipital horn syndrome; Trientine; Wilson's disease; Zinc

Indexed keywords

CERULOPLASMIN; COPPER; DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; HEPHAESTIN; HISTIDINE; MENKES PROTEIN; MONOPHENOL MONOOXYGENASE; PENICILLAMINE; PROTEIN LYSINE 6 OXIDASE; TETRATHIOMOLYBDIC ACID; THIOL OXIDASE; TRIENTINE; WILSON DISEASE PROTEIN; ZINC;

ANEMIA; ARTICLE; ATAXIA; CERULOPLASMIN BLOOD LEVEL; CHOREOATHETOSIS; CONNECTIVE TISSUE DISEASE; COPPER DEFICIENCY; COPPER METABOLISM; DIETARY INTAKE; DISEASE ASSOCIATION; DYSARTHRIA; DYSTONIA; EPILEPSY; FEVER; GASTRITIS; GENE DELETION; GENE MUTATION; GENETIC DISORDER; HOMEOSTASIS; HUMAN; INTESTINE BRUSH BORDER MEMBRANE; KINKY HAIR; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; LUPUS LIKE SYNDROME; MAGNETIC RESONANCE ANGIOGRAPHY; MASS SCREENING; MENKES SYNDROME; MUSCLE HYPOTONIA; MYOCLONUS; NEPHROTIC SYNDROME; NERVE DEGENERATION; NEUTROPENIA; PANCREATITIS; PROTEINURIA; RASH; RETINITIS; SMALL INTESTINE; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; URINARY TRACT INFECTION; WILSON DISEASE;

AGE FACTORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; COPPER; CUTIS LAXA; EHLERS-DANLOS SYNDROME; HEPATOLENTICULAR DEGENERATION; HUMANS; INFANT; INFANT, NEWBORN; LIVER NEOPLASMS; MASS SCREENING; MENKES KINKY HAIR SYNDROME;

EID: 84860505334     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012799320455     Document Type: Article

References (130)

1. Uriu-Adams, J. Y.; Scherr, R. E.; Lanoue, L.; Keen, C. L. Influence of copper on early development: Prenatal and postnatal considerations. BioFactors, 2010, 36 2, 136-152.
2. Lalioti, V.; Muruais, G.; Tsuchiya, Y.; Pulido, D; Sandoval, I. V. Molecular mechanisms of copper homeostasis. Front. Biosci., 2009, 14, 4878-4903.
3. Menkes, J. H; Alte, M.; Steigleder, G. K.; Weakley, D. R.; Sung, J. H. A sex-linked reccesive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics, 1962, 29, 764-769.
4. Danks, D. M.; Campbell, P. E.; Stevens, B. J.; Mayne, V.; Cartwright, E. Menkes's kinky hair syndrome. An inherited defect in copper absorption with widespread effects. Pediatrics, 1972, 50, 188-201.
5. Lazoff, S. G.; Rybak, J. J.; Parker, B. R.; Luzzatti, L. Skeletal dysplasia, occipital horns, diarrhea and obstructive uropathy - a new hereditary syndrome. Birth Defects Orig. Artic. Ser., 1975, 11 5, 71-74.
6. Wilson, S. A. K. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain, 1912, 34, 295-509.
7. Vulpe, C.; Levinson, B.; Whitney, S.; Packman, S.; Gitschier, J. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat. Genet., 1993, 3, 7-13.
8. Chelly, J.; Tümer, Z.; Tønnesen, T.; Petterson, A.; Ishikawa-Brush, Y.; Tommerup, N.; Horn, N.; Monaco, A. P. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat. Genet., 1993, 3 1, 14-19.
9. Mercer, J. F.; Livingston, J.; Hall, B.; Paynter, J. A.; Begy, C.; Chandrasekharappa, S.; Lockhart, P.; Grimes, A.; Bhave, M.; Siemieniak, D.; Glover, T. W. Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat. Genet., 1993, 3 1, 20-25.
10. Kaler SG, Gallo LK, Proud VK, Percy AK, Mark Y, Segal NA, Goldstein S, Holmes CS, Gahl WA. Occipital horn syndrome and a mild Menkes disease phenotype associated with splice mutations at the MNK locus. Nat. Genet., 1994, 8 2, 195-202.
11. Das, S.; Levinson, B.; Vulpe, C.; Whitney, S.; Gitschier, J.; Packman, S. Similar splicing mutations of the Menkes/mottled copper-transporting ATPase gene in occipital horn syndrome and the blotchy mouse. Am. J. Hum. Genet., 1995, 56 3, 570-576.
12. Bull, P. C.; Thomas, G. R.; Rommens, J. M.; Forbes, J. R.; Cox, D. W. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet., 1993, 5 4, 327-337.
13. Tanzi, R. E.; Petrukhin, K.; Chernov, I.; Pellequer, J. L.; Wasco, W.; Ross, B.; Romano, D. M.; Parano, E.; Pavone, L.; Brzustowicz, L. M.; Devoto, M.; Peppercorn, J.; Bush, A. I.; Sternlieb, I.; Pirastu, M.; Gusella, J. F.; Evgrafov, O.; Penchaszadeh, G. K.; Honig, B.; Edelman, I. S.; Soares, M. B.; Scheinberg, I. H.; Gilliam, T. C. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat. Genet., 1993, 5 4, 344-350.
14. Petrukhin, K.; Fischer, S. G.; Pirastu, M.; Tanzi, R. E.; Chernov, I.; Devoto, M.; Brzustowicz, L. M.; Cayanis, E.; Vitale, E.; Russo, J. J.; Matseoane, D.; Boukhgalter, B.; Wasco, W.; Figus, A. L; Loudianos, J.; Cao, A.; Sternlieb, I.; Evgrafov, O.; Parano, E.; Pavone, L.; Warburton, D.; Ott, J.; Penchaszadeh, G. K.; Scheinberg, I. H.; Gilliam, T. C. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nat. Genet., 1993, 5 4, 338-343.
15. Yamaguchi, Y.; Heiny, M. E.; Gitlin, J. D. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem. Biophys. Res. Commun., 1993, 197 1, 271-7.
16. Kodama, H.; Gu, Y. H.; Mizunuma, M. Drug targets in Menkes disease-prospective developments. Expert. Opin. Ther. Targets., 2001, 5 5, 625-635.
17. Kodama, H. and Fujisawa, C. Copper metabolism and inherited copper transporter disorders: molecular mechanisms, screening, and treatment. Metallomics, 2009, 1, 42-52.
18. Kodama, H.; Fujisawa, C.; Bhadhprasit, W. Pathology, clinical features and treatments of congenital copper metabolic disorders - Focus on neurologic aspects. Brain Dev., 2011, 243-51.
19. Culotte, V. C.; Gitlin, J. D.; Charles, R. S.; Arthur, L. B.; William, S. S.; David, V. The Metabolism and Molecular Basis of Inherited Disease. New York: McGRAWHILL, 2001, 3105-3126.
20. Van den Berghe, P. V. E.; Klomp, L. W. J. New developments in the regulation of intestinal copper absorption. Nutr. Rev., 2009, 67 11, 658-672.
21. Turnlund, J. R. Human whole-body copper metabolism. Am. J. Clin. Nutr., 1998, 67(Suppl), S960-S964.
22. Gupta, A. and Lutsenko, S. Human copper transporters: mechanism, role in human diseases and therapeutic potential. Future Med. Chem., 2009, 1 6, 1125-1142.
23. Miyayama, T.; Suzuki, K. T.; Ogura, Y. Copper accumulation and compartmentalization in mouse fibroblast lacking metallothionein and copper chaperone, Atox1. Toxicol. Appl. Pharmacol., 2009, 237 2, 205-213.
24. Rodriguez-Granillo, A.; Crespo, A.; Estrin, D. A.; Wittung-Stafshede, P. Copper-transfer mechanism from the human chaperone Atox1 to a metal-binding domain of Wilson disease protein. J. Phys. Chem. B., 2010, 114 10, 3698-3706.
25. Narindrasorasak, S.; Kulkarni, P.; Deschamps, P.; She, Y. M.; Sarkar, B. Characterization and copper binding properties of human COMMD1 (MURR1). Biochem., 2007, 46 11, 3116-3128.
26. Sarkar, B.; Roberts, EA. The puzzle posed by COMMD1, a newly discovered protein binding Cu (II). Metallomics, 2011, 3 1, 20-27.
27. van De Sluis, B.; Rothuizen, J.; Pearson, P. L.; van Oost, B. A.; Wijmenga, C. Identification of a new copper metabolism gene by positional cloning in a purebred dog population. Hum. Mol. Genet., 2002, 11 2, 165-73.
28. Tao, T. Y.; Liu, F.; Klomp, L.; Wijmenga, C.; Gitlin, J. D. The copper toxicosis gene product Murr1 directly interacts with the Wilson disease protein. J. Biol. Chem., 2003, 278 43, 41593-41596.
29. Miyayama, T.; Hiraoka, D.; Kawaji, F.; Nakamura, E.; Suzuki, N.; Ogra, Y. Roles of COMM-domain-containing 1 in stability and recruitment of the copper-transporting ATPase in a mouse hepatoma cell line. Biochem. J., 2010, 429 1, 53-61.
30. Kennerson, M. L.; Nicholson, G. A.; Kaler, S. G.; Kowalski, B.; Mercer, J. F. B.; Tang, J.; Llanos, R. M.; Chu, S.; Takata, R. I.; Speck-Martins, C. E.; Beats, J.; Almeida-Souza, L.; Fischer, D.; Timmerman, V.; Taylor, P. E.; Scherer, S. S.; Ferguson, T. A.; Bird, T. D.; Jonghe, P. D.; Feely, S. M. E.; Shy, M. E.; Garbern, J. Y. Missense mutations in the copper transporter gene ATP7A cause Xlinked distal hereditary motor neuropathy. Am. J. Hum. Genet., 2010, 86 3, 343-352.
31. Murata, Y.; Kodama, H.; Abe, T.; Ishida, N.; Nishimura, M.; Levinson, B.; Gitschier, J.; Packman, S. Mutation analysis and expression of the mottled gene in the macular mouse model of Menkes disease. Pediatr. Res., 1997, 42 4, 436-442.
32. Qian, Y.; Tiffany-Castiglioni, E.; Welsh, J.; Harris, E. D. Copper efflux from murine microvascular cells requires expression of the menkes disease Cu-ATPase. J. Nutr., 1998, 128 8, 1276-1282.
33. La Fontaine, S. and Mercer, J. F. Trafficking of the copper-ATPases, ATP7A and ATP7B: role in copper homeostasis. Arch. Biochem. Biophys., 2007, 463 2, 149-167.
34. Forbes, J. R. and Cox, D. W. Functional characterization of missense mutations Wilson disease mutation or normal variant? Am. J. Hum. Genet., 1998, 63 6, 1663-1674.
35. Tang, J.; Robertson, S. P.; Lem, K. E.; Godwin, S. C.; Kaler, S. G. Functional copper transport explains neurologic sparing in occipital horn syndrome. Genet. Med., 2006, 8 11, 711-718.
36. Tsivkovskii, R.; Eisses, J. F.; Kapian, J. H.; Lutsenko, S. Functional properties of the copper transporting ATPase ATP7B (the Wilson's disease protein) expressed in insect cells. J. Biol. Chem., 2002, 277 2, 976-983.
37. Gu, Y. H.; Kodama, H.; Shiga, K.; Nakata, S.; Yanagawa, Y.; Ozawa, H. A survey of Japanese patients with Menkes disease from 1990 to 2003: incidence and early signs before typical symptomatic onset, pointing the way to earlier diagnosis. J. Inherit. Metab. Dis., 2005, 28 4, 473-478.
38. Gu, Y. H.; Kodama, H.; Murata, Y.; Mochizuki, D.; Yanagawa, Y.; Ushijima, H. ATP7A gene mutations in 16 patients with Menkes disease and a patient with occipital horn syndrome. Am. J. Med. Genet., 2001, 99 3, 217-222.
39. Kodama, H. Gene defects and clinical aspects in Menkes disease and occipital horn syndrome. In: Massaro E ed. Handbook of Copper Pharmacology. Totowa (U. S. A.); Human Press, 2002, 319-338.
40. Møller, L. B.; Mogensen, M.; Horn, N. Molecular diagnosis of Menkes disease: Genotype-phenotype correlation. Biochimie, 2009, 91 10, 1273-1277.
41. Gu, Y. H.; Kodama, H.; Sato, E.; Mochizuki, D.; Yanagawa, Y.; Takayanagi, M.; Sato, K.; Ogawa, A.; Ushijima, H.; Lee, C. C. Prenatal diagnosis of Menkes disease by genetic analysis and copper measurement. Brain Dev., 2002, 24 7, 715-718.
42. Sirleto, P.; Surace, C.; Santos, H.; Bertini, E.; Tomaiuolo, A. C.; Lombardo, A.; Boenzi, S.; Bevivino, E.; Dionisi-Vici, C.; Angioni, A. Lyonization effects of the t (X;16) translocation on the phenotypic expression in a rare female with Menkes disease. Pediatr. Res., 2009, 65 3, 347-351.
43. Kodama, H.; Murata, Y. Molecular genetics and pathophysiology of Menkes disease. Pediatr. Int., 1999, 41 4, 430-435.
44. Kodama, H.; Abe, T.; Takama, M.; Takahashi, I.; Kodama, M.; Nishimura, M. Histochemical localization of copper in the intestine and kidney of macular mice: light and electron microscopic study. J. Histochem. Cytochem., 1993, 41 10, 1529-1535.
45. Kodama, H.; Meguro, Y.; Abe, T.; Rayner, M. H.; Suzuki, K. T.; Kobayashi, S.; Nishimura, M. Genetic expression of Menkes disease in cultured astrocytes of the macular mouse. J. Inherit. Metab. Dis., 1991, 14 6, 896-901.
46. Kodama, H. Recent developments in Menkes disease. J. Inherit. Metab. Dis., 1993, 16 4, 791-799.
47. Murata, Y.; Kodama, H.; Mori, Y.; Kobayashi, M.; Abe, T. Mottled gene expression and copper distribution in the macular mouse, an animal model for Menkes disease. J. Inherit. Metab. Dis., 1998, 21 3, 199-202.
48. Aguilar, M. J.; Chadwick, D. L.; Okuyama, K.; Kamoshita, S. Kinky hair disease. I. Clinical and pathological features. J. Neuropath. & Exper. Neurol., 1966, 25 4, 507-522.
49. Kodama, H.; Sato, E.; Yanagawa, Y.; Ozawa, H.; Kozuma, T. Biochemical indicator for evaluation of connective tissue abnormalities in Menkes' disease. J. Pediatr., 2003, 142 6, 726-728.
50. Kaler, SG.; Goldstein, DS.; Holmes, C.; Salemo, JA.; Gahl, WA. Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease. Ann. Neurol., 1993, 33 2, 171-175.
51. Agertt, F.; Crippa, A. C.; Lorenzoni, P. J.; Scola, R. H.; Bruck, I.; Paola, L.; Silvado, C. E.; Werneck, L. C. Menkes's disease: case report. Arq. Neuropsiquiatr., 2007;65, 157-160.
52. Kodama, H.; Murata, Y.; Kobayashi, M. Clinical manifestations and treatment of Menkes disease and its variants. Pediatr. Int., 1999, 41 4, 423-429.
53. Bahi-Buisson, N.; Kaminska, A.; Nabbout, R.; Barnerias, C.; Desguerre, I.; De Lonlay, P.; Mayer, M.; Plouin, P.; Dulac, O.; Chiron C. Epilepsy in Menkes disease: analysis of clinical stages. Epilepsia, 2006;47(2), 380-386.
54. Ozawa, H.; Otaki, U.; Gu, Y. H.; Kodama, H. The symptoms and treatment of 20 patients with Menkes disease in Japan (in Japanese). J. Jpn. Pediatr. Soc., 2009;113(8), 1234-1237.
55. Ito, H.; Mori, K.; Sakata, M.; Naito, E.; Harada, M.; Minato, M.; Kodama, H.; Gu, Y. H.; Kuroda, Y.; Kagami, S. Pathophysiology of the transient temporal lobe lesion in a patient with Menkes disease. Pediatr. Int., 2008, 50 6, 825-827.
56. Ozawa, H.; Kodama, H.; Murata, Y.; Takashima, S.; Noma, S. Transient temporal lobe changes and a novel mutation in a patient with Menkes disease. Pediatr. Int., 2001, 43 4, 437-440.
57. Ozawa, H.; Kodama, H.; Kawaguchi, H.; Mochizuki, T.; Kobayashi, M.; Igarashi, T. Renal function in patients with Menkes disease. Eur. J. Pediatr., 2003, 162 1, 51-52.
58. Donsante, A.; Tang, J.; Godwin, S. C.; Holmes, C. S.; Goldstein, D. S.; Bassuk, A.; Kaler, S. G. Differences in ATP7A gene expression underlie intrafamilial variability in Menkes disease/occipital horn syndrome. J. Med. Genet., 2007, 44 8, 492-497.
59. Matsuo, M.; Tasaki, R.; Kodama, H.; Hamasaki, Y. Screening for Menkes disease using the urine HVA/VMA ratio. J. Inherit. Metab. Dis., 2005, 28 1, 89-93.
60. Kaler, S. G.; Holmes, C. S.; Goldstein, D. S.; Tang, J.; Godwin, S. C.; Donsante, A.; Liew, C. J.; Sato, S.; Patronas, N. Neonatal diagnosis and treatment of Menkes disease. N. Engl. J. Med., 2008, 358 6, 605-614.
61. Sarkar, B. Treatment of Wilson and Menkes disease. Chem. Rev., 1999, 99 9, 2535-2544.
62. Sarkar, B.; Lingertat-Walsh, K.; Clarke, J. T. Copper-histidine therapy for Menkes disease. J. Pediatr., 1993, 123 5, 828-830.
63. Christodoulou, J.; Danks, D. M.; Sarkar, B.; Baerlocher, K. E.; Casey, R.; Horn, N.; Tümer, Z.; Clarke, J. T. Early treatment of Menkes disease with parenteral copper-histidine: long-term followup of four treated patients. Am. J. Med. Genet., 1998, 76 2, 154-164.
64. Kaler, S. G.; Tang, J.; Kaneski, C. R. Translation read-through of a nonsense mutation in ATP7A impacts treatment outcome in Menkes disease. Ann. Neurol., 2009, 65 1, 108-113.
65. Kaler, S. G.; Liew, C. J.; Donsante, A.; Hicks, J. D.; Sato, S.; Greenfield, J. C. Molecular correlates of epilepsy in early diagnosed and treated Menkes disease. J. Inherit. Metab. Dis., 2010, 33 5, 583-589.
66. Kodama, H.; Sato, E.; Gu, Y. H.; Shiga, K.; Fujisawa, C.; Kozuma, T. Effect of copper and diethyldithiocarbamate combination therapy on the macular mouse, an animal model of Menkes disease. J. Inherit. Metab. Dis., 2005, 28 6, 971-978.
67. Takeda, T.; Fujioka, H.; Nomura, S.; Ninomiya, E.; Fujisawa, C.; Kodama, H.; Shintaku, H. The effect of disulfiram with Menkes disease - a case report. J. Inherit. Metab. Dis., 2010, 33, S161.
68. Mak, C. M. and Lam, C. W. Diagnosis of Wilson's disease: a comprehensive review. Crit. Rev. Clin. Lab. Sci., 2008, 45 3, 263-290.
69. Gu, Y. H.; Kodama, H.; Du, S. L.; Gu, Q. J.; Sun, H. J.; Ushijima, H. Mutation spectrum and polymorphisms in ATP7B identified on direct sequencing of all exons in Chinese Han and Hui ethnic patients with Wilson's disease. Clin. Genet., 2003, 64 6, 479-484.
70. Panagiotakaki, E.; Tzetis, M.; Manolaki, N.; Loudianos, G.; Papatheodorou, A.; Manesis, E.; Nousia-Arvanitakis, S.; Syriopoulou, V.; Kanavakis, E. Genotype-phenotype correlations for a wide spectrum of mutations in the Wilson disease gene (ATP7B). Am. J. Med. Genet. A., 2004, 131 2, 168-173.
71. Gromadzka, G.; Schmidt, H. H.; Genschel, J.; Bochow, B.; Rodo, M.; Tarnacka, B.; Litwin, T.; Chabik, G.; Czlonkowska, A. Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease. Clin. Genet., 2005, 68 6, 524-532.
72. Barada, K.; El-Atrache, M.; El-Haji, I. I; Rida, K.; El-Hajjar, J.; Mahfoud, Z.; Usta, J. Homozygous mutations in the conserved ATP hinge region of the Wilson disease gene association with liver disease. J. Clin. Gastroenterol., 2010, 44 6, 432-439.
73. Weiss, K. H.; Runz, H.; Noe, B.; Gotthardt, D. N.; Merle, U.; Ferenci, P.; Stremmel, W.; Füllekrug, J. Genetic analysis of BIRC4/XIAP as a putative modifier gene of Wilson disease. J. Inherit. Metab. Dis., 2010. [Epub Ahead]
74. Gupta, A.; Chattopadhyay, I.; Mukherjee, S.; Sengupta, M.; Das, S. K.; Ray, K. A novel COMMD1 mutation Thr174Met associated with elevated urinary copper and signs of enhanced apoptotic cell death in a Wilson disease patient. Behav. Brain Funct., 2010, 6 33, 1-5.
75. Wu, J.; Forbes, J. R.; Chen, H. S.; Cox, D. W. The LEC rat has a deletion in the copper transporting ATPase gene homologous to the Wilson disease gene. Nat. Genet., 1994, 7 4, 541-545.
76. Masuda, R.; Yoshida, M. C.; Sasaki, M.; Dempo, K.; Mori, M. High susceptibility to hepatocellular carcinoma development in LEC rats with hereditary hepatitis. Jpn. J. Cancer Res., 1988, 79 7, 828-835.
77. Coronado, V.; Nanji, M.; Cox, D. W. The Jackson toxic milk mouse as a model for copper loading. Mamm. Genome, 2001, 12 10, 793-795.
78. Shim, H. and Harris, Z. L. Genetic defects in copper metabolism. J. Nutr., 2003, 133(5 Suppl 1), 1527S-1531S.
79. Hayashi, H.; Yano, M.; Fujita, Y.; Wakusawa, S. Compound overload of copper and iron in patients with Wilson's disease. Med. Mol. Morphol., 2006, 39 3, 121-126.
80. Merle, U.; Tuma, S.; Herrmann, T.; Muntean, V.; Volkmann, M.; Gehrke, S. G.; Stremmel, W. Evidence for a critical role of ceruloplasmin oxidase activity in iron metabolism of Wilson disease gene knockout mice. J. Gastroenterol. Hepatol., 2010, 25 6, 1144-1150.
81. Lorincz, M. T. Neurologic Wilson's disease. Ann. N. Y. Acad. Sci., 2010, 1184, 173-187.
82. Prashanth, L. K.; Sinha, S.; Taly, A. B.; Mahadevan, A.; Vasudev, M. K.; Shankar, S. K. Spectrum of epilepsy in Wilson's disease with electroencephalographic, MR imaging and pathological correlates. J. Neurol. Sci., 2010, 291(1-2), 44-51.
83. Kodama, H.; Okabe, I.; Yanagisawa, M.; Nomiyama, H.; Nomiyama, K.; Nose, O.; Kamoshita, S. Does CSF copper level in Wilson disease reflect copper accumulation in the brain? Pediatr. Neurol., 1988, 4 1, 35-37.
84. Kumagi, T.; Horiike, N.; Michitaka, K.; Hasebe, A.; Kawai, K.; Tokumoto, Y.; Nakanishi, S.; Furukawa, S.; Hiasa, Y.; Matsui, H.; Kurose, K.; Matsuura, B.; Onji M. Recent clinical features of Wilson's disease with hepatic presentation. J. Gastroenterol., 2004, 39 12, 1165-1169.
85. Sinha, S.; Taly, A. B.; Prashanth, L. K.; Ravishankar, S.; Arunodaya, G. R.; Vasudev, M. K. Sequential MRI changes in Wilson's disease with de-copper therapy: a study of 50 patients. Br. J. Radiol., 2007, 80, 744-749.
86. Sinha, S.; Taly, A. B.; Ravishankar, S. Wilson's disease: 31P and 1H MR spectroscopy and clinical correlation. Neuroradiology. 2010, DOI 10.1007/s00243-010-0661-1.
87. Zhuang, X. H.; Mo, Y.; Jiang, X. Y.; Chen, S. M. Analysis of renal impairment in children with Wilson's disease. World J. Pediatr., 2008, 4 2, 102-105.
88. Das, S. K. and Ray, K. Wilson's disease: an update. Nat. Clin. Pract. Neurol., 2006, 2 9, 482-493.
89. Roberts, E. A. and Schilsky, M. L. Diagnosis and treatment of Wilson disease: an update. Hepatology, 2008, 47 6, 2089-2111.
90. Oder, W.; Grimm, G.; Kollegger, H.; Ferenci, P.; Schneider, B.; Deecke, L. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. J. Neurol., 1991, 238 5, 281-287.
91. Foruny, J. R.; Boixeda, D.; López-Sanroman, A.; Vázquez-Sequeiros, E.; Villafruela, M.; Vázquez-Romero, M.; Rodríguez-Gandía, M.; de Argila, C. M.; Camarero, C.; Milicua, J. M. Usefulness of penicillamine-stimulated urinary copper excretion in the diagnosis of adult Wilson's disease. Scand. J. Gastroenterol., 2008, 43 5, 597-603.
92. Lin, C. W.; Er, T. K.; Tsai, F. J.; Lie, T. C.; Shin, P. Y.; Chang, J. G. Development of a high-resolution melting method for the screening of Wilson disease-related ATP7B gene mutations. Clin. Chim. Acta, 2010, 411(17-18), 1223-1231.
93. Ferenci, P.; Caca, K.; Loudianos, G.; Mieli-Vergani, G.; Tanner, S.; Sternlieb, I.; Schilsky, M.; Cox, D.; Berr, F. Diagnosis and phenotypic classification of Wilson disease. Liver Int., 2003, 23 3, 139-142.
94. Dhanwan, A. Evaluation of the scoring system for the diagnosis of Wilson's disease in children. Liver Int., 2005, 25 3, 680-681.
95. Prashanth, L. K.; Taly, A. B.; Sinha, S.; Arunodaya, G. R.; Swamy, H. S. Wilson's disease: diagnostic errors and clinical implications. J. Neurol. Neurosurg. Psychiatry., 2004, 75 6, 907-909.
96. Owada, M.; Suzuki, K.; Fukushi, M.; Yamauchi, K.; Kitagawa, T. Mass screening for Wilson's disease by measuring urinary holoceruloplasmin. J. Pediatr., 2002, 140 5, 614-616.
97. Yamaguchi, Y.; Aoki, T.; Arashima, S.; Ooura, T.; Takada, G.; Kitagawa, T.; Shigematsu, Y.; Shimada, M.; Kobayashi, M.; Itou, M.; Endo, F. Mass screening for Wilson's disease: results and recommendations. Pediatr. Int., 1999, 41 4, 405-408.
98. Nakayama, K.; Kubota, M.; Katoh, Y.; Sawada, Y.; Saito, A.; Nishimura, K.; Katsura, E.; Ichihara, N.; Suzuki, T.; Kouguchi, H.; Tamura, M.; Honma, H.; Kanzaki, S.; Itami, H.; Ohtake, A.; Kobayashi, K.; Ariga, T.; Fujieda, K.; Shimizu, N.; Aoki, T. Early and presymptomatic detection of Wilson's disease at the mandatory 3-year-old medical health care examination in Hokkaido Prefecture with the use of a novel automated urinary ceruloplasmin assay. Mol. Genet. Metab., 2008, 94 3, 363-367.
99. Brewer, G. J. and Askari, F. K. Wilson's disease: clinical management and therapy. J. Hepatol., 2005, 42(Suppl 1), S13-S21.
100. Walshe, J. M. Monitoring copper in Wilson's disease. Adv. Clin. Chem., 2010, 50, 151-163.
101. Hill, V. A.; Seymour, C. A.; Mortimer, P. S. Penicillamine-induced elastosis perforans serpiginosa and cutis laxa in Wilson's disease, Br. J. Dermatol., 2000, 142 3, 560-561.
102. Kodama, H.; Murata, Y.; Iitsyka, T.; Abe, T. Metabolism of administered triethylene tetramine dihydrochloride in humans. Life Sci., 1997, 61 9, 899-907.
103. Taylor, R. M.; Chen, Y.; Dhawan, A. Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King's Collage Hospital and review of the literature. Eur. J. Pediatr., 2009, DOI 10.1007/s00431-008-0886-8.
104. Brewer, G. J.; Hill, G. M.; Prasad, A. S.; Cossack, Z. T.; Rabbani, P. Oral zinc therapy for Wilson's disease. Ann. Intern. Med., 1983, 99 3, 314-319.
105. Hoogenraad, T. U. Paradigm shift in treatment of Wilson's disease: Zinc therapy now treatment of choice. Brain Dev., 2006, 28 3, 141-146.
106. Shimizu, N.; Fujiwara, J.; Ohnishi, S.; Sato, M.; Kodama, H.; Kohsaka, T.; Inui, A.; Fujisawa, T.; Tamai, H.; Ida, S.; Itoh, S.; Ito, M.; Horiike, N.; Harada, M.; Yoshino, M.; Aoki, T. Effects of longterm zinc treatment in Japanese patients with Wilson disease: efficacy, stability, and copper metabolism. Transl. Res., 2010, 156 6, 350-357.
107. Brewer, G. J.; Askari, F.; Dick, R. B.; Sitterly, J.; Fink, J. K.; Carlson, M.; Kluin, K. J.; Lorincz, M. T. Treatment of Wilson's disease with tetrathiomolybdate: V. control of free copper by tetrathiomolybdate and a comparison with trientine. Transl. Res., 2009, 154 2, 70-77.
108. Brewer, G. J.; Askari, F.; Lorincz, M. T.; Carlson, M.; Schilsky, M.; Kluin, K. J.; Hedera, P.; Moretti, P.; Fink, J. K.; Tanlanow, R.; Dick, R. B.; Sitterly, J. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch. Neurol., 2006, 63 4, 521-527.
109. Pestana Knight, E. M.; Gilman, S.; Selwa, L. Status epilepticus in Wilson's disease. Epileptic Disord., 2009, 11 2, 138-143.
110. Brewer, G. J. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. CNS Drugs, 2005, 19 3, 185-192.
111. Wiggelinkhuizen, M.; Tilanus, M. E. C.; Bollen, C. W.; Houwen, R. H. J. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment. Pharmacol. Ther., 2009, 29 9, 947-958.
112. Linn, F. H. H.; Houwen, R. H. J.; van Hattum, J.; van der Kleij, S.; van Erpecum, K. J. Long-term exclusive zinc monotherapy in symptomatic Wilson disease: Experience in 17 patients. Hepatol., 2009, 50 5, 1442-1452.
113. Duarte-Rojo, A.; Zepeda-Gomez, S.; Garcia-Leiva, J.; Remes-Troche, J. M.; Angeles-Angeles, A.; Torre-Delgadillo, A.; Olivera-Martinez, M. A. Liver transplantation for neurologic Wilson's disease: reflections on two cases within a Mexican cohort. Rev. Gastroenterol. Mex., 2009, 74 3, 218-223.
114. Komatsu, H.; Fujisawa, T.; Inui, A.; Sogo, T.; Sekine, I.; Kodama, H.; Uemoto, S.; Tanaka, K. Hepatic copper concentration in children undergoing living related liver transplantation due to Wilsonian fulminant hepatic failure. Clin. Transplant., 2002, 16 3, 227-232.
115. Masełbas, W.; Chabik, G.; Członkowska, A. Persistence with treatment in patients with Wilson disease. Neurol. Neurochir. Pol., 2010, 44 3, 260-263.
116. Tsubota, A.; Matsumoto, K.; Mogushi, K.; Nariai, K.; Namiki, Y.; Hoshina, S.; Hano, H.; Tanaka, H.; Saito, H.; Tada, N. IQGAP1 and vimentin are key regulator genes in naturally occurring hepatotumorigenesis induced by oxidative stress. Carcinogenesis, 2010, 31 3, 504-511.
117. Staib, F.; Hussain, S. P.; Hofseth, L. J.; Wang, X. W.; Harris, C. C. TP53 and liver carcinogenesis. Hum. Mutat., 2003, 21 3, 201-216.
118. Fryer, M. J. Potential of vitamin E as an antioxidant adjunct in Wilson's disease. Med. Hypotheses, 2009, 73 6, 1029-1030.
119. Brewer, G. J. Copper control as an antiangiogenic anticancer therapy: Lessons from treating Wilson's disease. Exp. Biol. Med., 2001, 226 7, 665-673.
120. Brewer, G. J. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J. Cell Mol. Med., 2003, 7 1, 11-20.
121. Tümer, Z. and Møller, L. B. Menkes disease. Eur. J. Hum. Genet., 2010, 18 5, 511-518.
122. Meskini, R. E.; Culotta, V. C.; Mains, R. E.; Eipper, B. A. Supplying copper to the cuproenzymes peptidylglycine α-amidating monooxygenase. J. Biol. Chem., 2003, 278 14, 12278-12284.
123. Chen, H.; Huang, G.; Su, T.; Gao, H.; Attieh, Z. K.; McKie, A. T.; Anderson, G. J.; Vulpe, C. D. Decrease hephaestin activity in the intestine of copper-deficient mice causes systemic iron deficiency. J. Nutr., 2006, 136 5, 1236-1241.
124. Riordan, J. F. 14-Structure and function of angiogenin. Ribonuclease, 1997, 445-489.
125. Ganz, T. Angiogenin: an antimicrobial ribonuclease. Nat. Immunol., 2003, 4 3, 213-214.
126. Hooper, L. V.; Stappenbeck, T. S.; Hong, C. V.; Gordon, J. I. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat. Immunol., 2003, 4 3, 269-273.
127. Toninello, A.; Pietrangeli, P.; Marchi, U. D.; Salvi, M.; Mondovi, B. Amine oxidases in apoptosis and cancer. Biochim. Biophys. Acta., 2006, 1765 1, 1-13.
128. Ogiwara, K.; Nogami, K.; Nishiya, K.; Shima, M. Plasmin-induced procoagulant effects in the blood coagulation: a crutial role of coagulation factor V and VIII. Blood Coagul. Fibrinolysis, 2010, 21 6, 568-576.
129. George, G. N.; Pickering, I. J.; Harris, H. H.; Gailer, J.; Klein, D.; Lichtmannegger, J.; Summer, K. K. Tetrathiomolybdate causes formation of hepatic copper-molybdenum clusters in an animal model of Wilson's disease. J. Am. Chem. Soc., 2003, 125 7, 1704-1705.
130. Brewer, G. J.; Terry, C. A.; Aisen, A. M.; Hill, G. M. Worsening of neurological syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch. Neurol., 1987, 44 5, 490-493.